The current investigation evaluated the physicochemical properties of ZER-NLC and determined its effect on human lymphoblastic leukemia (Jurkat) cell lines. The ZER-NLC is stable with high ZER-loading efficiency. The loaded particle was shown to be cytotoxic to Jurkat cells, suggesting it to be a potentially effective antileukemia treatment regime. ZER_NLC as a new drug-delivery method will contribute to the development of the local and international pharmaceutical industry particular in the development of new innovative drug-delivery systems.
Zerumbone (ZER) is a crystalline, sesquiterpene, phytochemical substance that was first isolated as a major compound from the rhizomes of Zingiber zerumbet (L.) smith. Although ZER has been shown to have anticancer properties, its poor water-solubility has hindered the development of this compound as a potent drug. Nanostructured lipid carrier (NLC) is second generation solid lipid nanoparticle composed of solid and liquid lipid that was produced by high pressure homogenization technique. The NLC has great potential as an innovative carrier for sustained drug-delivery. The main objective of this research is to develop, produce, and explore the potential of ZER-loaded NLC (ZER-NLC) as a treatment regime for cancers. The research evaluated the physicochemical properties of ZER-NLC by particle size (PS) and particle size distribution (PDI), using Photon Correlation Spectroscopy (PCS), particle charge, using Zeta Potential (ZP) measurements, state of drug and lipid modification, using differential scanning calorimeter (DSC) whilst Wide-angle X-ray Diffraction (WXRD), entrapment efficiency (EE) and drug loading capacity (DL) were determined by High Performance Liquid Chromatography (HPLC). In addition, the stability and in vitro drug release was determined by the modified Franz Diffusion Cell (FDC) system. The ZER-NLC is physically stable with a narrow size distribution containing up to 5% lipid. The current study further evaluated the cytotoxicity of ZER-NLC on a human lypmphoblastic leukemia (Jurkat) cell line in vitro. The MTT assay demonstrated that ZER-NLC has an IC50 of 5.64±0.385 microgram/mL on Jurkat cells which is similar to that of free ZER (5.397±0.431 microgram/mL). The results suggested that ZER-NLC has potential as sustained-released compound for the treatment of leukemias. This is a first report of the ZER-NLC production and its anti-leukemic agent.
By loading ZER in NLC improves the solubility of compound which allows it to used parenterally. ZER is not only antileukemia, but has been shown to effective towards cervical cancers. ZER-NLC provides an innovative and new method for the delivery of ZER treatment of diseases.